Pfizer shared good news on November 3, 2026. The big medicine company made more money than experts thought it would. It also raised its plan for the full year. That means it now thinks it will end the year even stronger.
What Happened
Pfizer told the world how it did in the third part of the year. That part ran from July to September. The company took in $16.58 billion. Experts had thought it would take in $15.92 billion. So Pfizer did better than they thought.
Profit means money left after a company pays its bills. Pfizer made $3.36 billion in profit. A year ago, it made $4.04 billion. So profit was lower than last year. But the result was still better than experts had hoped.
Stock means a small piece of a company. People who own stock own a small piece of that company. Pfizer shares went up more than 3% before the stock market opened. A share is one small piece of a company.
Why It Happened
Some of Pfizer’s newer medicines sold very well. Sales of its heart medicine Eliquis rose 29% to $2.19 billion. Sales of its Vyndaqel family of heart medicines rose 19% to $1.82 billion. Sales of its cancer medicine Padcev rose 44% to $1.16 billion.
Not all medicines did well. Sales of its Covid vaccine Comirnaty fell 52% to $1.22 billion. Sales of its Covid pill Paxlovid fell 69% to $188 million. Fewer people need these Covid products now. That is a big change from the pandemic years.
Pfizer is also trying to spend less money. It plans to save $7.2 billion by the end of 2027. It expects to save $4.5 billion by the end of 2026. Then it plans to save $2.7 billion more in 2027. Think of it like a family cutting waste at home so more money stays in the piggy bank.
The company also named a new money chief. Dave Denton will step down on December 31. Cecile Guegan will take over on January 1. She has worked at Pfizer since 2013. Denton joined the company in 2022. He plans to move back to Texas. He will stay on as an adviser for a short time.
Key Numbers in Simple Words
- Money taken in: $16.58 billion, up 8% from a year ago.
- Experts had expected: $15.92 billion.
- Profit: $3.36 billion, down from $4.04 billion a year ago.
- Adjusted profit per share: $0.92, while experts expected $0.79.
- New full-year money plan: $62 billion to $63.5 billion.
- New full-year profit per share plan: $3.05 to $3.15.
Why It Matters
This news matters for people who follow big companies. It shows Pfizer is less tied to Covid products now. Newer medicines are doing more of the work. That can make the company steadier over time.
It also matters for people who save money in stocks. When a company beats what experts expect, its shares often go up. That does not mean the shares will keep going up. It just shows one good report.
What Happens Next
People will watch the last three months of 2026. They will check if Pfizer hits its new, higher plan. They will also watch the new money chief in her first months in the job. And they will watch if the newer medicines keep growing.
Pfizer will also keep working on its cost cuts. If it saves as much as it plans, it will keep more of the money it takes in. You can also read our look at the big week ahead for markets in Big Week Ahead: Major Earnings, Powell and Key Jobs Data, November 3-7.
Final Thoughts
Pfizer had a better quarter than many people expected. Its newer medicines helped a lot. Its Covid products sold much less. The company now hopes for a stronger full year. The next report will show if that hope comes true.
Disclaimer: This article is for educational and informational purposes only and does not constitute financial advice.
Sources: CNBC: Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO and Reuters: Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat.
Leave a Reply